Top

Annals of Surgical Oncology

Published in:

01-03-2006 | Educational Review

Chemotherapy and Radiotherapy in the Treatment of Resectable Non–Small-Cell Lung Cancer

Authors: Eric D. Bernstein, MD, MPH, Scott M. Herbert, MD, Nasser H. Hanna, MD

Published in: Annals of Surgical Oncology | Issue 3/2006

Abstract

Background

Surgical resection remains the cornerstone of therapy for early-stage disease and offers the best chance for cure. Local and distant failure rates, however, remain unacceptably high with surgery alone. Radiation and systemic chemotherapy have been used to reduce recurrences in early-stage disease. Neoadjuvant and adjuvant strategies both offer sound theoretical benefit, but evidence supporting this has been lacking. The publication of a meta-analysis in 1995 triggered a reevaluation of adjuvant chemotherapy. Four randomized trials reported in the last 2 years support the use of adjuvant platinum-based chemotherapy.

Methods

This article reviews the history of clinical trials evaluating neoadjuvant and adjuvant therapy in non–small-cell lung cancer.

Results

Adjuvant chemotherapy improves 5-year survival rates by approximately 5%–15% compared with surgery alone.

Conclusions

Surgical resection followed by adjuvant chemotherapy is the standard of care treatment for patients with completely resected stage I, II, and IIIA non–small-cell lung cancer.

Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin 2004; 54:8–29PubMed

Mountain CF. The international system for staging lung cancer. Semin Surg Oncol 2000; 18:106–15CrossRefPubMed

Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ 1995; 311:899–909

Bernard A, Deschamps C, Allen MS, et al. Pneumonectomy for malignant disease: factors affecting early morbidity and mortality. J Thorac Cardiovasc Surg 2001; 121:1076–82CrossRefPubMed

Martin J, Ginsberg RJ, Abolhoda A, et al. Morbidity and mortality after neoadjuvant therapy for lung cancer: the risks of right pneumonectomy. Ann Thorac Surg 2001; 72:1149–54CrossRefPubMed

Siegenthaler MP, Pisters KM, Merriman KW, et al. Preoperative chemotherapy for lung cancer does not increase surgical morbidity. Ann Thorac Surg 2001; 71:1105–11; discussion 1111–2CrossRefPubMed

van der Hage JA, van der Velde CJH, Julien J, et al. Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol 2001; 19:4224–37PubMed

Pisters KM, Ginsberg RJ, Giroux DJ, et al. Induction chemotherapy before surgery for early-stage lung cancer: a novel approach. Bimodality Lung Oncology Team. J Thorac Cardiovasc Surg 2000; 119:429–39PubMed

Simpson-Herren L, Sanford AH, Holmquist JP. Effects of surgery on the cell kinetics of residual tumor. Cancer Treat Rep 1976; 60:1749–60PubMed

10.

Roth JA, Atkinson EN, Fossella F, et al. Long-term follow-up of patients enrolled in a randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. Lung Cancer 1998; 21:1–6CrossRefPubMed

11.

Rosell R, Gumez-Codina J, Camps C, et al. Preresectional chemotherapy in stage IIIA non-small-cell lung cancer: a 7-year assessment of a randomized controlled trial. Lung Cancer 1999; 26:7–14CrossRefPubMed

12.

Depierre A, Milleron B, Moro-Sibilot D, et al. Preoperative chemotherapy followed by surgery compared with primary surgery in resectable stage I (except T1N0), II, and IIIa non-small-cell lung cancer. J Clin Oncol 2002; 20:247–53CrossRefPubMed

13.

Betticher DC, Hsu Schmitz S, Totch M, et al. Mediastinal lymph node clearance after docetaxel-cisplatin neoadjuvant chemotherapy is prognostic of survival in patients with stage IIIA pN2 non-small-cell lung cancer: a multicenter phase II trial. J Clin Oncol 2003; 21:1752–9CrossRefPubMed

14.

Rosell R, Gatzemeier U, Betticher DC, et al. Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial. Ann Oncol 2002; 13:1539–49CrossRefPubMed

15.

Fossella F, Pereira JR, van Pawel J, et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol 2003; 21:3016–24CrossRefPubMed

16.

Kelly K, Crowley J, Bunn PA Jr, et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol 2001; 19:3210–8PubMed

17.

Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346:92–8CrossRefPubMed

18.

Pisters K, Vallieres E, Bunn P. S9900: a phase III trial of surgery alone or surgery plus preoperative (preop) paclitaxel/carboplatin (PC) chemotherapy in early stage non-small cell lung cancer (NSCLC): preliminary results (abstract 7012). J Clin Oncol 2005; 23(Suppl):16s

19.

Kim S, Sohn H, Lee W. Clinical significance of lymphatic/vascular tumor cells (LVT) and adjuvant chemotherapy (AC) after curative resection of non-small cell lung cancer (NSCLC) (abstract 7044). J Clin Oncol 2005; 23(Suppl):16s

20.

Warram J. Preoperative irradiation of cancer of the lung: final report of a therapeutic trial. A collaborative study. Cancer 1975; 36:914–25

21.

Shaw R, Paulson DL, Kee JL Jr. Treatment of superior sulcus tumor by irradiation followed by resection. Ann Surg 1961; 154:29–40

22.

Shields TW. Preoperative radiation therapy in the treatment of bronchial carcinoma. Cancer 1972; 30:1388–94PubMed

23.

Rusch VW, Giroux DJ, Kraut MJ, et al. Induction chemoradiotherapy and surgical resection for non-small cell lung carcinomas of the superior sulcus (Pancoast tumors): mature results of Southwest Oncology Group trial 9416 (Intergroup trial 0160) (abstract 2548). Proc Am Soc Clin Oncol 2003; 22:634

24.

Kunitoh H, Kato H, Tsuboi M, et al. A phase II trial for pre-operative chemoradiotherapy followed by surgical resection in Pancoast tumors: initial report of Japan Clinical Oncology Group trial (JCOG 9806) (abstract 2549). Proc Am Soc Clin Oncol 2003; 22:634

25.

Eberhardt W, Wilke H, Stmatis G, et al. Preoperative chemotherapy followed by concurrent chemoradiation therapy based on hyperfractionated accelerated radiotherapy and definitive surgery in locally advanced non-small-cell lung cancer: mature results of a phase II trial. J Clin Oncol 1998; 16:622–34PubMed

26.

Cyjon A, Nili M, Fink G, et al. Advanced non-small cell lung cancer: induction chemotherapy and chemoradiation before operation. Ann Thorac Surg 2002; 74:342–7CrossRefPubMed

27.

Albain KS, Rusch VW, Crowley JJ, et al. Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805. J Clin Oncol 1995; 13:1880–92PubMed

28.

Albain KS, Scott CB, Rusch VR, et al. Phase III comparison of concurrent chemotherapy plus radiotherapy (CT/RT) and CT/RT followed by surgical resection for stage IIIA(pN2) non-small cell lung cancer (NSCLC): initial results from intergroup trial 0139 (RTOG 93-09) (abstract 2497). Proc Am Soc Clin Oncol 2003; 22:621

29.

Thomas M, Mach HN, Ukena D, et al. Cisplatin/etoposide (PE) followed by twice-daily chemoradiation (hfRT/CT) versus PE alone before surgery in stage III non-small cell lung cancer (NSCLC): a randomized phase III trial of the German Lung Cancer Cooperative Group (GLCCG) (abstract 7004). Proc Am Soc Clin Oncol 2004; 22(14 Suppl):618s.

30.

Gaer JA, Goldstraw P. Intraoperative assessment of nodal staging at thoracotomy for carcinoma of the bronchus. Eur J Cardiothorac Surg 1990; 4:207–10CrossRefPubMed

31.

Keller SM, Adak S, Wagner H, et al. Mediastinal lymph node dissection improves survival in patients with stages II and IIIa non-small cell lung cancer. Eastern Cooperative Oncology Group. Ann Thorac Surg 2000; 70:358–65; discussion 365–6

32.

Pieterman RM, van Putten JW, Meuzelaar JJ, et al. Preoperative staging of non-small-cell lung cancer with positron-emission tomography. N Engl J Med 2000; 343:254–61CrossRefPubMed

33.

Mac Manus MP, Hicks RJ, Matthews JP, et al. Positron emission tomography is superior to computed tomography scanning for response-assessment after radical radiotherapy or chemoradiotherapy in patients with non-small-cell lung cancer. J Clin Oncol 2003; 21:1285–92CrossRefPubMed

34.

Effects of postoperative mediastinal radiation on completely resected stage II and stage III epidermoid cancer of the lung. The Lung Cancer Study Group. N Engl J Med 1986; 315:1377–81

35.

Feng QF, Wang M, Wang LJ, et al. A study of postoperative radiotherapy in patients with non-small-cell lung cancer: a randomized trial. Int J Radiat Oncol Biol Phys 2000; 47:925–9CrossRefPubMed

36.

Stephens RJ, Girling DJ, Bleehen NM, et al. The role of post-operative radiotherapy in non-small-cell lung cancer: a multicentre randomised trial in patients with pathologically staged T1-2, N1-2, M0 disease. Medical Research Council Lung Cancer Working Party. Br J Cancer 1996; 74:632–9PubMed

37.

Lafitte JJ, Ribet ME, Prevost BM, et al. Postresection irradiation for T2 N0 M0 non-small cell carcinoma: a prospective, randomized study. Ann Thorac Surg 1996; 62:830–4PubMed

38.

Dautzenberg B, Arriagada R, Chammard AB, et al. A controlled study of postoperative radiotherapy for patients with completely resected nonsmall cell lung carcinoma. Groupe d’Etude et de Traitement des Cancers Bronchiques. Cancer 1999; 86:265–73

39.

Postoperative radiotherapy in non-small-cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomised controlled trials. PORT Meta-analysis Trialists Group. Lancet 1998; 352:257–63

40.

Machtay M, Lee J, Shrager J, et al. Risk of death from intercurrent disease is not excessively increased by modern postoperative radiotherapy for high-risk resected non-small-cell lung carcinoma. J Clin Oncol 2001; 19:3912–7PubMed

41.

Sawyer TE, Bonner JA, Gould PM, et al. Effectiveness of postoperative irradiation in stage IIIA non-small cell lung cancer according to regression tree analyses of recurrence risks. Ann Thorac Surg 1997; 64:1402–7CrossRefPubMed

42.

Furuse K, Fukuoka M, Kawahara M, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol 1999; 17:2692–9PubMed

43.

Curran WJ, Scott CB, Langer CJ, et al. Long-term benefit is observed in a phase III comparison of sequential vs concurrent chemo-radiation for patients with unresected stage III NSCLC: RTOG 9410 (abstract 2499). Proc Am Soc Clin Oncol 2003; 22:621

44.

Pierre F, Maurice P, Gilles R, et al. A randomized phase III trial of sequential chemo-radiotherapy versus concurrent chemo-radiotherapy in locally advanced non small cell lung cancer (NSCLC) (GLOT-GFPC NPC 95-01 study) (abstract). Proc Am Soc Clin Oncol 2001; 20:312a

45.

Pisters KM, Kris MG, Gralla RJ, et al. Randomized trial comparing postoperative chemotherapy with vindesine and cisplatin plus thoracic irradiation with irradiation alone in stage III (N2) non-small cell lung cancer. J Surg Oncol 1994; 56:236–41PubMed

46.

Dautzenberg B, Chastang C, Arriagada R, et al. Adjuvant radiotherapy versus combined sequential chemotherapy followed by radiotherapy in the treatment of resected nonsmall cell lung carcinoma. A randomized trial of 267 patients. GETCB (Groupe d’Etude et de Traitement des Cancers Bronchiques). Cancer 1995; 76:779–86PubMed

47.

Wolf M, Müller H, Seifart U, et al. Randomized phase III trial of adjuvant radiotherapy vs. adjuvant chemotherapy followed by radiotherapy in patients with N2 positive non small cell lung cancer (NSCLC) (abstract 1242). Proc Am Soc Clin Oncol 2001; 20.

48.

Chemotherapy for non-small cell lung cancer. Non-small Cell Lung Cancer Collaborative Group. Cochrane Database Syst Rev 2000; 2:CD002139

49.

Scagliotti GV, Fossati R, Torri V, et al. Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell Lung cancer. J Natl Cancer Inst 2003; 95:1453–61PubMed

50.

The International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004; 350:351–60CrossRef

51.

Delbado C, Syz N, Michiels S, et al. Adding a second or a third drug to a chemotherapy regimen in patients with advanced non-small-cell lung carcinoma (NSCLC): a meta-analysis of the literature (abstract 2507). Proc Am Soc Clin Oncol 2003; 22:623

52.

Strauss GM, Herndon J, Maddaus MA, et al. Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in stage IB non-small cell lung cancer (NSCLC): report of Cancer and Leukemia Group B (CALGB) protocol 9633 (abstract 7019). J Clin Oncol 2004; 22(Suppl):14S

53.

Winton TL, Livingston R, Johnson D, et al. A prospective randomised trial of adjuvant vinorelbine (VIN) and cisplatin (CIS) in completely resected stage 1B and II non small cell lung cancer (NSCLC) Intergroup JBR.10 (abstract 7018). J Clin Oncol 2004; 22(Suppl):14s

54.

Douillard J, Rosell R, Delen M, et al. ANITA: phase III adjuvant vinorelbine (N) and cisplatin (P) versus observation (OBS) in completely resected (stage I-III) non-small-cell lung cancer (NSCLC) patients (pts): final results after 70-month median follow-up (abstract 7013). J Clin Oncol 2005; 23(Suppl):16s

55.

Wada H, Miyahara R, Tanaka F, et al. Postoperative adjuvant chemotherapy with PVM (cisplatin + vindesine + mitomycin C) and UFT (uracil + tegafur) in resected stage I-II NSCLC (non-small cell lung cancer): a randomized clinical trial. West Japan Study Group for Lung Cancer Surgery (WJSG). Eur J Cardiothorac Surg 1999; 15:438–43CrossRefPubMed

56.

Wada H, Hitomi S, Teramatsu T. Adjuvant chemotherapy after complete resection in non-small-cell lung cancer. West Japan Study Group for Lung Cancer Surgery. J Clin Oncol 1996; 14:1048–54

57.

A randomized trial of postoperative adjuvant chemotherapy in non-small cell lung cancer (the second cooperative study). The Study Group of Adjuvant Chemotherapy for Lung Cancer (Chubu, Japan). Eur J Surg Oncol 1995; 21:69–77

58.

Imaizumi M. A randomized trial of postoperative adjuvant chemotherapy for p-stage 1 non-small cell lung cancer (4th cooperative study). Lung Cancer 2003; 41(Suppl 2):S54.

59.

Kato H, Ichinose Y, Ohta M, et al. A randomized trial of adjuvant chemotherapy with uracil-tegafur for adenocarcinoma of the lung. N Engl J Med 2004; 350:1713–21CrossRefPubMed

60.

Hamada C, Ohta M, Wada H, et al. Survival benefit of oral UFT for adjuvant chemotherapy after completely resected non-small-cell lung cancer (abstract 7002). J Clin Oncol 2004; 22(Suppl):14s

61.

Kikuchi T, Daigo Y, Katagiri T, et al. Expression profiles of non-small cell lung cancers on cDNA microarrays: identification of genes for prediction of lymph-node metastasis and sensitivity to anti-cancer drugs. Oncogene 2003; 22:2192–205CrossRefPubMed

62.

Yanagisawa K, Shyr Y, Xu B, et al. Proteomic patterns of tumour subsets in non-small-cell lung cancer. Lancet 2003; 362:433–9CrossRefPubMed

63.

Downey RJ, Akhurst T, Gihen M, et. al. Preoperative F-18 fluorodeoxyglucose-positron emission tomography maximal standardized uptake value predicts survival after lung cancer resection. J Clin Oncol 2004; 22:3255–60CrossRefPubMed

64.

Sandler AB, Grey R, Brahmer J, et al. Randomized phase II/III trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC #704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): an Eastern Cooperative Oncology Group (ECOG) trial E4599 (abstract 4). Proc Am Soc Clin Oncol 2005; 350:404–5

65.

Blum RH. Adjuvant chemotherapy for lung cancer—a new standard of care. N Engl J Med 2004; 350:404–5CrossRefPubMed

Title: Chemotherapy and Radiotherapy in the Treatment of Resectable Non–Small-Cell Lung Cancer
Authors: Eric D. Bernstein, MD, MPH
Scott M. Herbert, MD
Nasser H. Hanna, MD
Publication date: 01-03-2006
Publisher: Springer-Verlag
Published in: Annals of Surgical Oncology / Issue 3/2006
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI: https://doi.org/10.1245/ASO.2006.01.015

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Chemotherapy and Radiotherapy in the Treatment of Resectable Non–Small-Cell Lung Cancer

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 3/2006

Surgery in the Era of Gene Expression Profiling–Based Prediction and Individualized, Neoadjuvant Breast Cancer Therapy: The Beginning of the End?

Is Sentinel Lymph Node Biopsy Appropriate in Patients With Thin Melanomas: Too Early To Tell?

The Clinical Value of Parasternal Sentinel Node Biopsy in Breast Cancer

Results of Sentinel Lymph Node Biopsy in Patients With Thin Melanoma

Improved Staging With Pretreatment Positron Emission Tomography/Computed Tomography in Low Rectal Cancer

Validation of a Breast Cancer Nomogram for Predicting Nonsentinel Lymph Node Metastases After a Positive Sentinel Node Biopsy